FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754452874> ?p ?o ?g. }

• W2754452874 endingPage "258" @default.
• W2754452874 startingPage "1" @default.
• W2754452874 abstract "Background Synovitis (inflamed joint synovial lining) in rheumatoid arthritis (RA) can be assessed by clinical examination (CE) or ultrasound (US). Objective To investigate the added value of US, compared with CE alone, in RA synovitis in terms of clinical effectiveness and cost-effectiveness. Data sources Electronic databases including MEDLINE, EMBASE and the Cochrane databases were searched from inception to October 2015. Review methods A systematic review sought RA studies that compared additional US with CE. Heterogeneity of the studies with regard to interventions, comparators and outcomes precluded meta-analyses. Systematic searches for studies of cost-effectiveness and US and treatment-tapering studies (not necessarily including US) were undertaken. Mathematical model A model was constructed that estimated, for patients in whom drug tapering was considered, the reduction in costs of disease-modifying anti-rheumatic drugs (DMARDs) and serious infections at which the addition of US had a cost per quality-adjusted life-year (QALY) gained of £20,000 and £30,000. Furthermore, the reduction in the costs of DMARDs at which US becomes cost neutral was also estimated. For patients in whom dose escalation was being considered, the reduction in number of patients escalating treatment and in serious infections at which the addition of US had a cost per QALY gained of £20,000 and £30,000 was estimated. The reduction in number of patients escalating treatment for US to become cost neutral was also estimated. Results Fifty-eight studies were included. Two randomised controlled trials compared adding US to a Disease Activity Score (DAS)-based treat-to-target strategy for early RA patients. The addition of power Doppler ultrasound (PDUS) to a Disease Activity Score 28 joints-based treat-to-target strategy in the Targeting Synovitis in Early Rheumatoid Arthritis (TaSER) trial resulted in no significant between-group difference for change in Disease Activity Score 44 joints (DAS44). This study found that significantly more patients in the PDUS group attained DAS44 remission ( p = 0.03). The Aiming for Remission in Rheumatoid Arthritis (ARCTIC) trial found that the addition of PDUS and grey-scale ultrasound (GSUS) to a DAS-based strategy did not produce a significant between-group difference in the primary end point: composite DAS of < 1.6, no swollen joints and no progression in van der Heijde-modified total Sharp score (vdHSS). The ARCTIC trial did find that the erosion score of the vdHS had a significant advantage for the US group ( p = 0.04). In the TaSER trial there was no significant group difference for erosion. Other studies suggested that PDUS was significantly associated with radiographic progression and that US had added value for wrist and hand joints rather than foot and ankle joints. Heterogeneity between trials made conclusions uncertain. No studies were identified that reported the cost-effectiveness of US in monitoring synovitis. The model estimated that an average reduction of 2.5% in the costs of biological DMARDs would be sufficient to offset the costs of 3-monthly US. The money could not be recouped if oral methotrexate was the only drug used. Limitations Heterogeneity of the trials precluded meta-analysis. Therefore, no summary estimates of effect were available. Additional costs and health-related quality of life decrements, relating to a flare following tapering or disease progression, have not been included. The feasibility of increased US monitoring has not been assessed. Conclusion Limited evidence suggests that US monitoring of synovitis could provide a cost-effective approach to selecting RA patients for treatment tapering or escalation avoidance. Considerable uncertainty exists for all conclusions. Future research priorities include evaluating US monitoring of RA synovitis in longitudinal clinical studies. Study registration This study is registered as PROSPERO CRD42015017216. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2754452874 created "2017-09-25" @default.
• W2754452874 creator A5000419712 @default.
• W2754452874 creator A5004498996 @default.
• W2754452874 creator A5033485095 @default.
• W2754452874 creator A5041422025 @default.
• W2754452874 creator A5051630157 @default.
• W2754452874 creator A5052330918 @default.
• W2754452874 creator A5064302550 @default.
• W2754452874 creator A5076943613 @default.
• W2754452874 creator A5080267247 @default.
• W2754452874 creator A5085346534 @default.
• W2754452874 date "2018-04-01" @default.
• W2754452874 modified "2023-10-14" @default.
• W2754452874 title "What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis" @default.
• W2754452874 cites W108172154 @default.
• W2754452874 cites W113797418 @default.
• W2754452874 cites W1449540316 @default.
• W2754452874 cites W1483140880 @default.
• W2754452874 cites W1485925639 @default.
• W2754452874 cites W1491476885 @default.
• W2754452874 cites W1523575018 @default.
• W2754452874 cites W1539853698 @default.
• W2754452874 cites W1596295297 @default.
• W2754452874 cites W1726059930 @default.
• W2754452874 cites W1812129566 @default.
• W2754452874 cites W1904507660 @default.
• W2754452874 cites W1964809414 @default.
• W2754452874 cites W1965066261 @default.
• W2754452874 cites W1965701802 @default.
• W2754452874 cites W1966425460 @default.
• W2754452874 cites W1966643984 @default.
• W2754452874 cites W1966765909 @default.
• W2754452874 cites W1969576641 @default.
• W2754452874 cites W1969990762 @default.
• W2754452874 cites W1972274662 @default.
• W2754452874 cites W1972333902 @default.
• W2754452874 cites W1974168352 @default.
• W2754452874 cites W1979628524 @default.
• W2754452874 cites W1983077736 @default.
• W2754452874 cites W1983134858 @default.
• W2754452874 cites W1983778161 @default.
• W2754452874 cites W1984825022 @default.
• W2754452874 cites W1985658357 @default.
• W2754452874 cites W1985763670 @default.
• W2754452874 cites W1986795777 @default.
• W2754452874 cites W1988152642 @default.
• W2754452874 cites W1994865189 @default.
• W2754452874 cites W1994980683 @default.
• W2754452874 cites W1997471433 @default.
• W2754452874 cites W2000253156 @default.
• W2754452874 cites W2000546397 @default.
• W2754452874 cites W2000832741 @default.
• W2754452874 cites W2000905503 @default.
• W2754452874 cites W2001950449 @default.
• W2754452874 cites W2001957699 @default.
• W2754452874 cites W2003550964 @default.
• W2754452874 cites W2005429018 @default.
• W2754452874 cites W2006206256 @default.
• W2754452874 cites W2006277452 @default.
• W2754452874 cites W2007205421 @default.
• W2754452874 cites W2008189117 @default.
• W2754452874 cites W2008302815 @default.
• W2754452874 cites W2010201260 @default.
• W2754452874 cites W2014363662 @default.
• W2754452874 cites W2015007283 @default.
• W2754452874 cites W2015143860 @default.
• W2754452874 cites W2015265440 @default.
• W2754452874 cites W2017067157 @default.
• W2754452874 cites W2017933473 @default.
• W2754452874 cites W2019159305 @default.
• W2754452874 cites W2021820094 @default.
• W2754452874 cites W2024610927 @default.
• W2754452874 cites W2025291152 @default.
• W2754452874 cites W2025591723 @default.
• W2754452874 cites W2026335977 @default.
• W2754452874 cites W2026867831 @default.
• W2754452874 cites W2027004865 @default.
• W2754452874 cites W2034613861 @default.
• W2754452874 cites W2034845852 @default.
• W2754452874 cites W2035554341 @default.
• W2754452874 cites W2035691186 @default.
• W2754452874 cites W2036702384 @default.
• W2754452874 cites W2036988937 @default.
• W2754452874 cites W2037734288 @default.
• W2754452874 cites W2038013635 @default.
• W2754452874 cites W2038891063 @default.
• W2754452874 cites W2040293701 @default.
• W2754452874 cites W2041803731 @default.
• W2754452874 cites W2042447378 @default.
• W2754452874 cites W2044921283 @default.
• W2754452874 cites W2044940757 @default.
• W2754452874 cites W2045632335 @default.
• W2754452874 cites W2047563709 @default.
• W2754452874 cites W2048206778 @default.
• W2754452874 cites W2050580972 @default.
• W2754452874 cites W2052664721 @default.
• W2754452874 cites W2053086289 @default.

• next